These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 34516670)
1. Comparison between Liu Y; Dong Y; Liu J; Zhang X; Lin M; Xu B Prostate; 2021 Dec; 81(16):1329-1336. PubMed ID: 34516670 [TBL] [Abstract][Full Text] [Related]
2. Enhancing prostate cancer diagnosis and reducing unnecessary biopsies with [ Fu Y; Zhao M; Chen J; Wen Q; Chen B Sci Rep; 2024 Jul; 14(1):15525. PubMed ID: 38969741 [TBL] [Abstract][Full Text] [Related]
3. Prospective Comparison of PET Imaging with PSMA-Targeted Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492 [TBL] [Abstract][Full Text] [Related]
4. [ Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers. Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220 [No Abstract] [Full Text] [Related]
6. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304 [TBL] [Abstract][Full Text] [Related]
7. Detection of prostate cancer with Bodar YJL; Jansen BHE; van der Voorn JP; Zwezerijnen GJC; Meijer D; Nieuwenhuijzen JA; Boellaard R; Hendrikse NH; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN World J Urol; 2021 Jul; 39(7):2439-2446. PubMed ID: 33079250 [TBL] [Abstract][Full Text] [Related]
8. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer. Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798 [TBL] [Abstract][Full Text] [Related]
11. Semiquantitative Parameters in PSMA-Targeted PET Imaging with Li X; Rowe SP; Leal JP; Gorin MA; Allaf ME; Ross AE; Pienta KJ; Lodge MA; Pomper MG J Nucl Med; 2017 Jun; 58(6):942-946. PubMed ID: 27932557 [No Abstract] [Full Text] [Related]
12. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. Gorin MA; Marashdeh W; Ross AE; Allaf ME; Pienta KJ; Pomper MG; Rowe SP Nucl Med Commun; 2017 Sep; 38(9):795-798. PubMed ID: 28704341 [TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
14. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970 [TBL] [Abstract][Full Text] [Related]
15. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635 [TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of PI-RADS v2 and PI-RADS v1. Polanec S; Helbich TH; Bickel H; Pinker-Domenig K; Georg D; Shariat SF; Aulitzky W; Susani M; Baltzer PA Eur J Radiol; 2016 Jun; 85(6):1125-31. PubMed ID: 27161062 [TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen PET/MRI validation of MR textural analysis for detection of transition zone prostate cancer. Bates A; Miles K Eur Radiol; 2017 Dec; 27(12):5290-5298. PubMed ID: 28608163 [TBL] [Abstract][Full Text] [Related]
18. Prospective analysis of clinically significant prostate cancer detection with [ Bodar YJL; Zwezerijnen BGJC; van der Voorn PJ; Jansen BHE; Smit RS; Kol SQ; Meijer D; de Bie K; Yaqub M; Windhorst BAD; Hendrikse HNH; Vis AN; Oprea-Lager DE Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727 [TBL] [Abstract][Full Text] [Related]
19. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with Pienta KJ; Gorin MA; Rowe SP; Carroll PR; Pouliot F; Probst S; Saperstein L; Preston MA; Alva AS; Patnaik A; Durack JC; Stambler N; Lin T; Jensen J; Wong V; Siegel BA; Morris MJ J Urol; 2021 Jul; 206(1):52-61. PubMed ID: 33634707 [TBL] [Abstract][Full Text] [Related]
20. Multiparametric MRI in detection and staging of prostate cancer. Boesen L Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]